Timely and relevant thoracic oncology news brought to you by the only global association dedicated to the multidisciplinary study of lung cancer.

Timely and relevant thoracic oncology news brought to you by the only global association dedicated to the multidisciplinary study of lung cancer.

Presidential Symposium

January 28, 2021

Nivolumab Boosted Survival in Relapsed Mesothelioma

By

Presidential Symposium

Nivolumab significantly improved investigator-reported progression-free survival and overall survival compared with placebo in patients with relapsed malignant mesothelioma, according to preliminary results of the CONFIRM phase III trial presented during […]
January 28, 2021

KEYNOTE-598: Dual PD-1 and CTLA-4 Checkpoint Blockade Confers No Therapeutic Benefit Beyond PD-1 Blockade Alone in PD-L1–Positive NSCLC

By

Presidential Symposium, WCLC 2020 Archive

Patients with metastatic NSCLC with a PD-L1 tumor proportion score (TPS) ≥ 50% face greater toxicity without the benefit of enhanced efficacy when ipilimumab is combined with pembrolizumab in the […]

January 28, 2021

LCMC3 Findings Indicate Neoadjuvant Atezolizumab Safe, Efficacious in Resectable Stage IB-IIIB NSCLC

By

Presidential Symposium, WCLC 2020 Archive

Primary results of the phase II Lung Cancer Mutation Consortium (LCMC) 3 clinical trial suggest that neoadjuvant atezolizumab may be a worthwhile treatment option for selected patients with resectable stage […]
January 28, 2021

Genetically Tailored Treatment Approach Did Not Improve Survival in Stage II-III NSCLC

By

Presidential Symposium

Evaluation of mRNA expression of selected genes to tailor adjuvant chemotherapy did not improve survival outcomes in patients with resected stage II-III NSCLC, according to results of the ITACA study, […]